Please login to the form below

Not currently logged in
Email:
Password:

Mayzent

This page shows the latest Mayzent news and features for those working in and with pharma, biotech and healthcare.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta

The new EU approval for Kesimpta builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).

Latest news

  • J&J’s MS drug ponesimod receives approval in the US J&J’s MS drug ponesimod receives approval in the US

    Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod).

  • Novartis’ MS therapy Mayzent approved by NICE Novartis’ MS therapy Mayzent approved by NICE

    Mayzent then received approval from the European Commission (EC) earlier this year, again for the treatment of adults with active SPMS. ... According to NICE, around 11, 000 people with SPMS will now be eligible to receive Mayzent treatment.

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).

  • Novartis builds its case for novel MS treatment ofatumumab Novartis builds its case for novel MS treatment ofatumumab

    The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....